SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.62
+0.13 (+0.31%)
At close: 4:00PM EST

41.62 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close41.49
Open41.77
Bid41.68 x 1000
Ask42.77 x 900
Day's Range41.48 - 41.93
52 Week Range37.43 - 45.86
Volume703,773
Avg. Volume1,188,747
Market Cap102.751B
Beta (3Y Monthly)0.49
PE Ratio (TTM)21.45
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.86 (4.49%)
Ex-Dividend Date2018-05-09
1y Target Est49.00
Trade prices are not sourced from all markets
  • PR Newswire7 hours ago

    FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

    BRIDGEWATER, N.J., Jan. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range.

  • Alnylam & Medison Partner to Market RNAi Products in Israel
    Zacks2 days ago

    Alnylam & Medison Partner to Market RNAi Products in Israel

    Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

  • Merck's Partner Gets FDA Nod for Herceptin Biosimilar
    Zacks2 days ago

    Merck's Partner Gets FDA Nod for Herceptin Biosimilar

    Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

  • Top Ranked Income Stocks to Buy for January 21st
    Zacks3 days ago

    Top Ranked Income Stocks to Buy for January 21st

    Top Ranked Income Stocks to Buy for January 21st

  • Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
    Zacks6 days ago

    Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

    Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

  • The Wall Street Journal7 days ago

    [$$] Corporate Europe Faces 'Unbearable' Uncertainty With U.K. Exit

    ’s failure to get U.K. parliamentary approval for a deal to split the country from the European Union adds significant pressure on companies as they plan for the now greater possibility of an abrupt and disorderly exit. The repudiation has opened up a variety of possible outcomes considered unlikely until recently, from Britain crashing out of the EU without a deal to a new referendum on whether to leave at all. “It’s patients don’t get medicine.” He has spent almost two years planning how to insulate the French drugmaker from a messy Brexit.

  • Regeneron (REGN) Sails Steady on Label Expansion of Drugs
    Zacks7 days ago

    Regeneron (REGN) Sails Steady on Label Expansion of Drugs

    Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily8 days ago

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • PR Newswire9 days ago

    FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

    BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination.

  • CNBC9 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • CNBC9 days ago

    Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement

    In the past, pharmaceutical companies have attributed high prices to innovation, arguing that new and improved drugs are naturally more expensive . Looking at wholesale data for around 27,000 prescription drugs, Hernandez and her colleagues found that, between 2008 and 2016, brand-name oral prescription drugs rose 9 percent annually, while injectable drugs increased 15 percent per year.

  • 6 Stocks With Low Price-Sales Ratios
    GuruFocus.com12 days ago

    6 Stocks With Low Price-Sales Ratios

    Sanofi tops the list

  • 3 Biotech Stocks Bubbling Away
    Investopedia13 days ago

    3 Biotech Stocks Bubbling Away

    Merger and acquisition activity in the healthcare sector has biotech stocks soaring. Explore three stocks feeling the tailwind.

  • Financial Times14 days ago

    [$$] Sanofi and Novo Nordisk press ahead with US insulin prices rises

    have raised prices of insulin in the US, despite political pressure as diabetics protest and lobby lawmakers over the rising cost of the essential medicine. Sanofi increased the price of its three main insulin brands by between 4.4 per cent and 5.2 per cent last week, while Novo Nordisk increased the price of its insulin products by just under 5 per cent on Tuesday. Depending on the dose and brand, the list prices for insulin products vary between $300 and $400.

  • TheStreet.com14 days ago

    Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

    just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.

  • Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
    Zacks15 days ago

    Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

    Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

  • Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
    Zacks16 days ago

    Regeneron, Sanofi Restructure Immuno-Oncology Collaboration

    Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.

  • Reuters16 days ago

    U.S. top court rejects Amgen over cholesterol medication patent fight

    Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. The justices declined to hear Amgen's appeal seeking reinstatement of a jury verdict it won against Regeneron and Sanofi in the dispute in which Amgen accused its rivals of infringing its patents relating to its competing drug Repatha and sought to block sales of Praluent.

  • Sanofi to pay Regeneron $462 million in revised immuno-oncology deal
    Reuters16 days ago

    Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

    Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery programme costs for the last quarter of 2018.

  • Reuters16 days ago

    UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal

    Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes.

  • Reuters17 days ago

    Drugmakers Sanofi, Regeneron restructure immuno-oncology deal

    Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million. The companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently, while Regeneron retains all rights to its other immuno-oncology discovery and development programs. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery program costs for the last quarter of 2018, and up to $120 million in other development costs.

  • Why Novavax's Stock Is Surging Today
    Motley Fool20 days ago

    Why Novavax's Stock Is Surging Today

    Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.

  • Emergent (EBS) Files Application for Emergency Use of NuThrax
    Zacks24 days ago

    Emergent (EBS) Files Application for Emergency Use of NuThrax

    Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

  • These Are the Stocks Warren Buffett Bought and Sold in 2018
    GOBankingRates26 days ago

    These Are the Stocks Warren Buffett Bought and Sold in 2018

    These are the moves Berkshire Hathaway made this year.

  • Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine
    Zacks27 days ago

    Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine

    Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.